<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228227</url>
  </required_header>
  <id_info>
    <org_study_id>ROMA II</org_study_id>
    <nct_id>NCT01228227</nct_id>
  </id_info>
  <brief_title>ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading</brief_title>
  <acronym>ROMAIIReload</acronym>
  <official_title>High Loading ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis : Comparison With Atorvastatin High Dose Reloading.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gennaro Sardella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increase in cardiac biomarkers has been shown to occur in 5% to 30% of patients after
      otherwise successful percutaneous coronary interventions (PCIs)(1) Apart from side-branch
      occlusion, intimal dissection and coronary spasm, a possible aetiology of myonecrosis after
      PCI might be distal embolization of atherogenic materials from plaque disruption,(2 )causing
      obstruction of blood flow at capillary level resulting in micro-infarction.(3,4 )Recent
      studies have suggested that pretreatment with Atorvastatin may be associated with a reduction
      in infarct size after elective PCI. (5-7 ). Actually the standard pretreatment in patients
      undergoing elective coronary-PCI and already treated with aspirin is clopidogrel loading dose
      administration before procedure.(8,9)The investigators compared a high (80mg) re-loading dose
      of Atorvastatin with a high loading dose of Rosuvastatin (40 mg) both administered within 24h
      before the procedure in reducing the rate of periprocedural MI. Therefore, the investigators
      will conduct a single center, prospective randomized study to assess whether a single, high
      (80mg) loading (within 24h)dose of Atorvastatin compared with a single loading dose of
      Rosuvastatin (20 mg) is effective in preventing elevation of biomarkers of MI after elective
      coronary stent implantation. We evaluate the incidence of MACCE(occurring of cardiac death,
      myocardial infarction (including periprocedural myonecrosis) and stroke at 30 days 6 and 12
      month follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial enzymes arise</measure>
    <time_frame>12- 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>1-6-12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Assess the Periprocedural Myocardial Necrosis</condition>
  <arm_group>
    <arm_group_label>ROSUVASTATIN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ATORVASTATIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATORVASTATIN 80 mg</intervention_name>
    <description>reload of Atorvastatin 80 mg before the procedure</description>
    <arm_group_label>ATORVASTATIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ROSUVASTATIN 40 mg</intervention_name>
    <description>reload of rosuvastatin 40 mg before the procedure</description>
    <arm_group_label>ROSUVASTATIN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with stable angina

        Exclusion Criteria:

        Baseline myocardial enzyme rise
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <last_update_submitted>January 3, 2013</last_update_submitted>
  <last_update_submitted_qc>January 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Gennaro Sardella</investigator_full_name>
    <investigator_title>Associate Professor in Cardiology</investigator_title>
  </responsible_party>
  <keyword>Myonecrosis</keyword>
  <keyword>Percutaneous Angioplasty</keyword>
  <keyword>Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

